Further studies are needed to investigate the unknown mechanisms through which programmed cell death modalities are involved in the production of pro-inflammatory mediators (e.g., IL-1β), and the amplification of chronic tissue inflammation in autoimmune diseases. This evidence concerns the gene IL1B and autoimmune disease.